Charles Flagg, who is stricken with Alzheimer’s disease, sits for an infusion while participating in a study on the drug Aducanumab at Butler Hospital in Providence, R.I. New results were released on the experimental medicine whose maker claims it can slow the decline of Alzheimer’s disease, the most common form of dementia. (AP Photo/Charles Krupa)
A company that claims to have the first drug to slow mental decline from Alzheimer’s disease made its case to scientists Thursday but left them sharply divided over whether there’s enough evidence of effectiveness for the medicine to warrant federal approval.
Excitement and skepticism have surrounded aducanumab since its developers stopped two studies…
Efesbet, kullanıcı dostu bir platform sunarak oyuncuların rahatça bahis yapmalarını ve kazanç elde etmelerini sağlar. Kazandıran içeriklerle dolu platformlar, oyun severlerin ilk tercihleri arasında...
Bahis severler, en iyi platformlar sayesinde hızlı ödemeler ve cazip bonuslarla daha verimli bir oyun deneyimi yaşar. Kullanıcılar, platformların sunduğu deneme bonuslarıyla oyun dünyasına...
